Head-to-head · Cost-Efficiency Index
Nurx vs VigorMeds
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Nurx
Shoppers who specifically want FDA-approved brand-name Wegovy/Zepbound access through an established telehealth brand and don't want a compounded product.
Visit NurxVigorMeds
Cost-first shoppers who want a needle-free sublingual GLP-1 that's meaningfully cheaper than the injectable version, from named physicians.
Visit VigorMedsThe verdict
Nurx and VigorMeds tie on the Cost-Efficiency Index at 50/100, so neither wins outright on the numbers. For most shoppers we'd start with Nurx (ranked #411, a hair above #416) — Shoppers who specifically want FDA-approved brand-name Wegovy/Zepbound access through an established telehealth brand and don't want a compounded product. But VigorMeds is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Nurx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Nurx | VigorMeds |
|---|---|---|
| Cost-Efficiency Index | 50/100 | 50/100 |
| Semaglutide / mo | $1,379/mo (brand Wegovy) | $199/mo (starting dose, compounded) |
| Tirzepatide / mo | $1,079/mo (brand Zepbound) | $299/mo (starting dose, compounded) |
| Semaglutide / yr (modeled) | $16,548 | $2,388 |
| Tirzepatide / yr (modeled) | $12,948 | $3,588 |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Compounded only |
| Rank here | #411 | #416 |
Nurx
50/100Where the value is
- Backed by Thirty Madison, an established telehealth parent company that also runs Keeps and Cove
- Prescribes genuinely FDA-approved brand-name GLP-1s (Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, Victoza) rather than a compounded substitute
- Names two Medical Directors on its team page (Dr. Peter Young, Dr. Neil Zlatniski)
The tradeoffs
- Sells NO compounded semaglutide or tirzepatide at any price — a prior dataset's '$179/mo compounded' figure does not describe any product actually on this site
- Nurx's own advertised medication prices ($1,000-$1,300/mo) are Nurx's estimate of what the PHARMACY will charge, not a price Nurx guarantees or collects — actual cost varies by pharmacy and insurance
VigorMeds
50/100Where the value is
- Both injectable and needle-free sublingual forms of semaglutide ($139/mo) and tirzepatide ($159/mo) — the sublingual tier is $60-$140/mo cheaper than the injectable tier
- Named, credentialed clinicians reviewing cases: Dr. Anthony Kane MD, Dr. Claudia Mondragon MD, Dr. Kevin Kargman MD, Stephanie Kowatch MSN FNP-C
- 'Pay upon medical approval' — no charge until a provider signs off on treatment, plus a 30-day satisfaction guarantee
The tradeoffs
- The dedicated 'States We Serve' page names zero actual states in its crawlable content — only vague buckets like 'Coming soon' and 'Room to grow'
- The FIRST100 promo code discounts whichever tier is chosen by $100 for the first month, so the price shown at signup is not the ongoing rate
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.